Work

684 - Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY

Year: 2024

Type: article

Study design: Study Protocol

Source: British Journal of Dermatology

DOI: 10.1093/bjd/ljae266.058

Authors: Linda Stein Gold, Stephan Weidinger, Delphine Staumont-Salle, Saeko Nakajima, Eric L Simpson, Marjolein de Bruin Weller, Sonya Davey, Kassim Rahawi, Charlotte Bernigaud

Institutions: Henry Ford Health, University Hospital Schleswig-Holstein, Centre Hospitalier Universitaire de Lille, Kyoto University, Oregon Health & Science University, Utrecht University, University Medical Center Utrecht, Sanofi (France)

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401436012

FWCI: 1.026

Cites:

Cited by: 3

Related to: 10